(Q40172287)

18 September 2017

title

Docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer: a phase II study (English)

1 reference

18 September 2017

1 reference

1 reference

1 reference

Devon Evans

1

1 reference

18 September 2017

Thomas Miner

2

1 reference

18 September 2017

David Iannitti

3

1 reference

18 September 2017

Paul Akerman

4

1 reference

18 September 2017

Dennis Cruff

5

1 reference

18 September 2017

Christine Maia-Acuna

6

1 reference

18 September 2017

David Harrington

7

1 reference

18 September 2017

Fadlo Habr

8

1 reference

18 September 2017

Bharti Chauhan

9

1 reference

18 September 2017

Anna Berkenblit

10

1 reference

18 September 2017

Keith Stuart

11

1 reference

18 September 2017

Dina Sears

12

1 reference

18 September 2017

Teresa Kennedy

13

1 reference

18 September 2017

Howard Safran

14

1 reference

18 September 2017

publication date

1 September 2007

1 reference

18 September 2017

1 reference

18 September 2017

volume

25

1 reference

18 September 2017

issue

6

1 reference

18 September 2017

page(s)

445-448

1 reference

Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F07357900701358025

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701358025

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701358025

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701358025

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701358025

Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701358025

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701358025

Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701358025

Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701358025

10.1080/07357900701358025

21 January 2018

Identifiers

DOI

1 reference

18 September 2017

1 reference